Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 53.98M P/E - EPS this Y -29.80% Ern Qtrly Grth -
Income -92.5M Forward P/E -0.76 EPS next Y -5.40% 50D Avg Chg 2.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 1.10 EPS next 5Y - 52W High Chg -57.00%
Recommedations 3.00 Quick Ratio 3.34 Shares Outstanding 60.82M 52W Low Chg 60.00%
Insider Own 7.28% ROA -41.42% Shares Float 48.80M Beta 1.75
Inst Own 46.03% ROE -105.78% Shares Shorted/Prior 165.27K/284.52K Price 0.89
Gross Margin - Profit Margin - Avg. Volume 745,032 Target Price 5.00
Oper. Margin - Earnings Date Oct 31 Volume 432,573 Change -5.93%
About Surface Oncology, Inc.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

SURF Chatroom

User Image MoneyTree82 Posted - 1 week ago

$CHRS let’s keep moving up 10-20 cents per day until we are back above $6 super cheap! Remember when we were acquiring $SURF and the price was range bound in low $5 until deal got closed! Just goes to show you it is all about what the big money wants to do! When they decide this goes up! We will go up fast! $XBI

User Image MoneyTree82 Posted - 1 month ago

$CHRS at the same time retail has never been in control of this stock… it has always been the big money pushing the tape higher or lower $SURF deal price stay exactly where it needed to… moment it was done … tape moved where they wanted it to… surf value complete gone in share price after deal was done in about 1 month🤔 It is encouraging analysts are still seeing Pt at $13 forward looking is good! $XBI

User Image MoneyTree82 Posted - 2 months ago

$CHRS seeking Alpha says M&A this year is going to be a big deal! We have to be a target with several cash generating products! Many companies buy a deal with a speculative hope… a company could buy us and have the cash flows while developing the $SURF oncology potential!

User Image PrimeT17 Posted - 2 months ago

$SURF $DRMA As reliable as Old Faithful. Dermata Therapeutics stock slowly losing volume by the day. They'll pump her up within the next few weeks. If you catch her right you can bag 40% to 80%. Just don't hold!

User Image Dealeyplaza1963 Posted - 3 months ago

$CHRS can someone explain the $SURF CVRs and when or how they get assigned a value.

User Image Larrygor Posted - 3 months ago

$CHRS $surf was good at $10 and $chrs at $14! now combine and $24 it is!

User Image brenda8winkle Posted - 4 months ago

$SURF What happened to this ticker? It doesn’t show the value in my brokerage account anymore. Did we get a new ticker? Can someone help me please?

User Image MoneyTree82 Posted - 4 months ago

$CHRS this has so far to run… please someone post chart from last December! We have more products approved… earning more revenue then at that time… farther along in FDA approval process... $SURF acquisition finished so we are now an oncology company… generating revenue and our market cap is lower by more than half at that time of that massive run higher in the stock!!! Huge institutional ownership! Fed just hinted that debt products will be cheaper in 2024 even though most of our debt isn’t played out until 2026 Price target $11 … closed under $2.50 today This needs to rip higher in a big way! Time for a big Santa clause rally to n this stock! $XBI $NASDAQ

User Image Larrygor Posted - 4 months ago

@T7Boeing ark aslo bought $surf around $10 only to be sold ti $CHRS for $1 so your following if ark purchases are dumb

User Image MoneyTree82 Posted - 5 months ago

$CHRS would love for the company to PR support for share price and shareholders! We went from $5.40 during $SURF acquisition and have lost massive amounts in of shareholder value! Time move higher… $2.00 is way to cheap! $PFE

User Image TrendyChart Posted - 5 months ago

Upcoming Earnings Report: $SURF Surface Oncology will be reporting on 11/17/2023 at 6:00AM | Will this stock deliver favorable or unfavorable earnings?

User Image Jalu06 Posted - 5 months ago

$SURF insane that we almost lost everything in not even 2 weeks after a fda approval

User Image MoneyTree82 Posted - 5 months ago

$CHRS i have never seen a onslaught like this where there isn’t a cause? That is why this is so brutally painful! Earning weren’t great earn this fiscal year we stayed in $4-5 range … Tori is approved! We miss by a small amount with improving revenue revenues and we drop 60% this was $3.60 pre earnings something doesn’t feel right? $SURF was a $1 when we closed on their shares so $CHRS is worth 63 cents 🤔 how?

User Image FE123 Posted - 5 months ago

$VCNX licensee agreement from $SURF with milestone payments! $CHRS buys $SURF $VCNX partnerered with $MRK Does $VCNX get a buyout from $MRK or $CHRS ?

User Image MoneyTree82 Posted - 10/30/23

$CHRS this was $5.20 before news when $SURF acquisition finalized! We got a huge runway if the right money gets behind us the next few days! $LLY $ABBV $MRK

User Image Fomoninja Posted - 10/28/23

$CHRS $SURF

User Image Larrygor Posted - 10/28/23

$CHRS my guess it will retract on monday and slowly be building the accumulation phase going into earnings! kind if BS i was here for Tori since $7 average! then $SURF acquisition drop to $5. then delay into $2.65 and now on approval of a blockbuster drug its up to $3.34! market is screwed! look at $blue every FDA approval caused 20% trim and downward movement! with Joe Biden behind the wheel uncertainty and wild west with no oversight is evident!

User Image TrendyChart Posted - 10/26/23

Upcoming Earnings Report: $SURF Surface Oncology will be reporting on 11/06/2023 at 6:00AM | Do you anticipate good or bad earnings for this stock?

User Image MoneyTree82 Posted - 10/26/23

@Train23 me too! Heavy bag! Hoping for reversal! Hate saying that cuz traders always say “hope” isn’t a strategy, but everything is positive for $CHRS … accept for the share price🤦‍♂️ Thought we would be low teens when this close to Tori approval and then add $SURF asset to our balance sheet and yet we are hovering g around 300 million market cap mind blown🤷‍♂️

User Image Jalu06 Posted - 10/24/23

$SURF Novartis ditched again many assets, but NZV930 is still in the pipeline. All in all they don’t have any pd1 now, so I don’t really know how a potential next trial could be designed. Saw some clinical data and if CD73 is expressed, CD73 could be useful. It increased ORR and PFS in several independent trials and compounds.

User Image Fomoninja Posted - 5 months ago

$CHRS 16.75 average price target high of 20, $SURF alone was a 20 target for me Lol! I'm increasing my target to the 40.00 's. If any Shorty's say anything 80.00! 💎💎👐👐👨‍🚀👨‍🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🌛🌛🪐🪐🪐 https://www.benzinga.com/analyst-ratings/23/10/35381353/analyst-expectations-for-coherus-biosciencess-future

User Image Bigman13 Posted - 6 months ago

$CHRS i had like 2 or 3 $SURF shares and now .98 of 1 $CHRS shares…does this seem right? Didn’t even realize they was merging

User Image MoneyTree82 Posted - 6 months ago

$CHRS I wonder how much selling was a by product of $SURF shareholders not wanting to hold their shares they received. —- would love for this to get above $5 or $10 so more institutional buyers would jump in for a position!

User Image Sam1381 Posted - 6 months ago

$SURF Why this ticker is no longer available in the market?

User Image neofeudal Posted - 6 months ago

$CHRS $LLY $ABBV $SURF $PNT

User Image MoneyTree82 Posted - 6 months ago

$CHRS did anyone notice $LLY bought out $PNT for 1.3 billion dollars … they are in late stage development of a cancer treatment to fight prostate cancer. They had 103 million shares. $CHRS has a 106 million shares and Tori is about to be approve for many cancer treatments… along with the purchase of $SURF our cancer pipeline looks very robust! If you don’t think we are undervalued. I don’t know what you are looking at or comparing. We are so massively undervalued I am shocked we have not been purchased already! Hopefully the market realizes his miss-priced we are or a larger player comes in and buys at a reasonable premium! Either way analysts price targets range from $12-20 and that seems low for a commercial stage medical company! $ABBV $LLY

User Image ForsakenOne Posted - 6 months ago

$CHRS simple fact of the matter is, MMs are moving it lower between each other a penny at a time. Low volume = easy manipulation. Until more people start buying this is our fate. Same way it went in $SURF. Well bleed into nothing.

User Image GSMITH10107 Posted - 6 months ago

$CHRS this is ugly, i was saying the chart in a scary downtrend a week ago, and it only has gotten worse. I really liked the company but the chart reminds me so much of $SURF , ironically who they acquired

User Image ForsakenOne Posted - 6 months ago

$CHRS what’s this 7 trading sessions in a row now. Yea this is $SURF 2.0. Just wait until the volume continues to drop off cuz no one wants to buy and the sellers can’t sell at those prices without heavy losses.

User Image ForsakenOne Posted - 09/29/23

$CHRS sure glad my $SURF shares have gotten converted for an additional 30% lose already.

Analyst Ratings
Wedbush Neutral Jun 20, 23
Baird Neutral Jun 20, 23
HC Wainwright & Co. Neutral Jun 20, 23
HC Wainwright & Co. Buy May 5, 23
Baird Outperform May 4, 23
Wedbush Outperform Mar 10, 23
HC Wainwright & Co. Buy Mar 10, 23
Baird Outperform Nov 3, 22
HC Wainwright & Co. Buy Nov 3, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Adams Chandra Deputy GC Deputy GC Aug 01 Sell 0.94 3,901 3,667 30,899 08/11/23
FEES JESSICA Chief Financial Offi.. Chief Financial Officer Aug 01 Sell 0.94 9,434 8,868 101,915 08/11/23
ONEILL ALISON Chief Medical Office.. Chief Medical Officer Aug 01 Sell 0.94 7,042 6,619 56,686 08/11/23
ROSS ROBERT W. Chief Executive Offi.. Chief Executive Officer Aug 01 Sell 0.94 16,713 15,710 83,193 08/11/23
RATH HENRY C. Chief Business Offic.. Chief Business Officer Aug 03 Sell 1.72 5,676 9,763 32,324 08/05/22
ONEILL ALISON Chief Medical Office.. Chief Medical Officer Aug 03 Sell 1.72 4,463 7,676 63,728 08/05/22
ROSS ROBERT W. Chief Executive Offi.. Chief Executive Officer Aug 03 Sell 1.72 10,594 18,222 99,906 08/05/22
FEES JESSICA Chief Financial Offi.. Chief Financial Officer Aug 03 Sell 1.72 5,980 10,286 111,349 08/05/22
Palombella Vito J. Chief Scientific Off.. Chief Scientific Officer Aug 03 Sell 1.72 4,463 7,676 87,212 08/05/22
Goater Jeff Director Director Jul 21 Sell 6.10 127,778 779,446 129,222 01/14/22
FEES JESSICA Chief Financial Offi.. Chief Financial Officer Jul 21 Sell 6.10 19,854 121,109 79,329 01/14/22
Palombella Vito J. Chief Scientific Off.. Chief Scientific Officer Jul 21 Sell 6.10 26,325 160,582 53,675 01/14/22
ROSS ROBERT W. Chief Executive Offi.. Chief Executive Officer Jul 21 Sell 6.10 33,500 204,350 54,500 01/14/22
Nogelo Liisa I Chief Legal Officer Chief Legal Officer Jul 21 Sell 6.10 26,325 160,582 53,675 01/14/22
ONEILL ALISON Chief Medical Office.. Chief Medical Officer Mar 01 Sell 6.1 14,809 90,335 30,191 01/14/22